1.Influences of inter-implant distances on the accuracy of intraoral scanning techniques
Acta Universitatis Medicinalis Anhui 2024;59(10):1875-1880
Objective To assess the influence of inter-implant distances on the accuracy of intraoral scanning im-pressions in vitro.Methods A master cast model with different inter-implant distances was scanned by laboratory and intraoral scanners,which were used as the reference and intraoral scan data.The distance and angular devia-tions of the scan bodies corresponding to the reference and intraoral digital scan standard tessellation language(STL)files were measured and calculated in a three-dimensional analysis software.The one-sample t-test,Spearman's correlation analysis,Brown-Forsythe F test,Games-Howell post-hoc test,and Levene's test were used for comparisons(α=0.05).Results The overall distance and angular deviations of the intraoral digital scan were(27.48±18.14)μm and(0.24±0.19)°,within clinically acceptable limits(P<0.001).The inter-implant distances exhibited a significant positive correlation with both the scanning distance and angular deviations in terms of scanning trueness.The angular deviation differed significantly between the 1-2 group(8.13 mm)and the other distance groups.Additionally,inter-implant distances affected the precision of the intraoral scanner(P<0.05).Conclusion The findings of this study indicate that intraoral scanning impressions of complete-arch implant-sup-ported prostheses are within clinically acceptable ranges of accuracy.Inter-implant distances≤8.13 mm can result in a higher accuracy of intraoral scanning.Increased inter-implant distances can adversely affect intraoral scanning accuracy.
2.One case of developmental epileptic encephalopathy caused by NR4A2 gene variation and literature review
Shiyan QIU ; Shaoxia SUN ; Li YANG ; Yufen LI ; Liyun XU ; Bing XIA ; Ying HUA
Chinese Journal of Neurology 2023;56(8):909-914
Objective:To analyze the clinical characteristics of a child with developmental epileptic encephalopathy caused by NR4A2 gene mutation, and to summarize the clinical phenotypes and genotypes to improve the clinician′s understanding of this disease. Methods:The clinical data of a child with developmental epileptic encephalopathy admitted to Linyi People′s Hospital in August 2022 were collected, video electroencephalogram, craniocerebral magnetic resonance imaging and family whole exon sequencing were improved, and the suspected mutation sites were verified by Sanger sequencing. Relevant literature was consulted to summarize the clinical phenotypes and genetic characteristics of nervous system diseases caused by NR4A2 gene. Results:It was found that there was a heterozygous missense mutation at the locus c.866G>A (p.A289H) of NR4A2 gene in the child, which was a de novo mutation, and both parents were wild type. According to the American Society of Medical Genetics and Genomics variation classification, it was assessed as a suspected pathogenic variation. Through literature review, there were 16 related cases reported internationally, with clinical phenotypes including mental retardation/mental retardation, language disorders, seizures, muscle tone changes and different psychological and behavioral problems. Conclusions:The NR4A2 gene is not only associated with dopa responsive disorders, but also with neurological development, intellectual impairment, language development delay, and epilepsy. The mutation of NR42A gene c.866G>A (p.A289H) is the genetic cause of the patient, and the detection of this locus expands the NR4A2 gene spectrum. NR4A2 gene is one of the pathogenic genes of developmental epileptic encephalopathy.
3.Correlation between Expression of CD47 Molecule in Patients with Newly Diagnosed Adult Acute Myeloid Leukemia and Clinical Prognosis.
Jing PAN ; Yuan-Yuan ZHANG ; Xia-Xia JIAO ; Lei-Na SONG ; Cai-Qin LIN ; Su-Li WANG ; Bin ZHU ; Shao-Ying PAN ; Zhi-Yong DING ; Wen-Li ZHAO
Journal of Experimental Hematology 2022;30(4):1071-1078
OBJECTIVE:
To investigate the expression of CD47 molecules in patients with newly diagnosis of adult acute myeloid leukemia (AML) and its correlation with clinical prognosis.
METHODS:
20 patients with acute myeloid leukemia diagnosed in Shanghai Fengxian District Central hospital from April 2020 to October 2021 and 5 cases with non malignant hematological diseases in the control group were collected, and the expression of CD47 in single nuclear cells of bone marrow and peripheral blood was detected by real-time fluorescence quantitative polymerase chain reaction (qPCR). Combined with the blood image, bone marrow smears, flow cytometry, chromosome and gene detection, ECOG score, etc. during the patient's initial diagnosis, the relationship between the patient's prognosis and CD47 was evaluated.
RESULTS:
The expression of CD47 in bone marrow (P=0.0115) and peripheral blood mononuclear cells (P=0.0069) in new diagnosis AML patients was significantly higher than that of controls. In bone marrow mononuclear cells, the total survival time of patients with high CD47 expression was less than that of CD47 low expression patients (P=0.036). There was statistical significance in difference stratification group (P=0.012), but there was no statistical significance between CD47 expression and survival time in peripheral blood mononuclear cells (P=0.116). There were no statistical significance between bone marrow mononuclear cell CD47 expression and gene mutation fusion genes related to leukemia , CD34+, CD38+, CD123+ (P>0.05). The proportion of bone marrow protocells in AML patients was >50%, the ECOG score was >2 points, MLLELL fusion gene and chromosome prognosis stratification were all risk factors affecting the survival of patients (P=0023, 0.036, 0.012, 0.001, respectively). The high expression of bone marrow CD47 in AML patients indicated a high risk of recurrence (P=0.017).
CONCLUSION
The high expression of bone marrow mononuclear cell CD47 in AML patients indicates poorer survival and higher risk of recurrence.
Adult
;
CD47 Antigen
;
China
;
Humans
;
Leukemia, Myeloid, Acute/genetics*
;
Leukocytes, Mononuclear/pathology*
;
Prognosis
4.COVID-19 in the immunocompromised population: data from renal allograft recipients throughout full cycle of the outbreak in Hubei province, China.
Weijie ZHANG ; Fei HAN ; Xiongfei WU ; Zhendi WANG ; Yanfeng WANG ; Xiaojun GUO ; Song CHEN ; Tao QIU ; Heng LI ; Yafang TU ; Zibiao ZHONG ; Jiannan HE ; Bin LIU ; Hui ZHANG ; Zhitao CAI ; Long ZHANG ; Xia LU ; Lan ZHU ; Dong CHEN ; Jiangqiao ZHOU ; Qiquan SUN ; Zhishui CHEN
Chinese Medical Journal 2021;135(2):228-230
5.Low-intensity pulsed ultrasound stimulates proliferation of stem/progenitor cells: what we need to know to translate basic science research into clinical applications.
Yan TAN ; Yang GUO ; Amanda B REED-MALDONADO ; Zheng LI ; Guiting LIN ; Shu-Jie XIA ; Tom F LUE
Asian Journal of Andrology 2021;23(6):602-610
Low-intensity pulsed ultrasound (LIPUS) is a promising therapy that has been increasingly explored in basic research and clinical applications. LIPUS is an appealing therapeutic option as it is a noninvasive treatment that has many advantages, including no risk of infection or tissue damage and no known adverse reactions. LIPUS has been shown to have many benefits including promotion of tissue healing, angiogenesis, and tissue regeneration; inhibition of inflammation and pain relief; and stimulation of cell proliferation and differentiation. The biophysical mechanisms of LIPUS remain unclear and the studies are ongoing. In recent years, more and more research has focused on the relationship between LIPUS and stem/progenitor cells. A comprehensive search of the PubMed and Embase databases to July 2020 was performed. LIPUS has many effects on stem cells. Studies show that LIPUS can stimulate stem cells in vitro; promote stem cell proliferation, differentiation, and migration; maintain stem cell activity; alleviate the problems of insufficient seed cell source, differentiation, and maturation; and circumvent the low efficiency of stem cell transplantation. The mechanisms involved in the effects of LIPUS are not fully understood, but the effects demonstrated in studies thus far have been favorable. Much additional research is needed before LIPUS can progress from basic science research to large-scale clinical dissemination and application.
Cell Proliferation
;
Humans
;
Signal Transduction
;
Stem Cells/radiation effects*
;
Ultrasonic Therapy/methods*
;
Ultrasonic Waves
6.Preliminary exploration of the mechanism of Qingfei Paidu decoction against novel coronavirus pneumonia based on network pharmacology and molecular docking technology
Hao WU ; Jia-qi WANG ; Yu-wei YANG ; Tian-yi LI ; Yi-jia CAO ; Yu-xia QU ; Yu-jie JIN ; Chen-ning ZHANG ; Yi-kun SUN
Acta Pharmaceutica Sinica 2020;55(3):374-383
Traditional Chinese medicine (TCM) network pharmacology and molecular docking technology were applied to explore the mechanism of anti-coronavirus pneumonia (coronavirus disease 2019, COVID-19) of Qingfei Paidu decoction. The Chinese Pharmacopoeia (2015 edition) and Traditional Chinese Medicine Systems Pharmacology (TCMSP), OMIM (Online Mendelian Inheritance in Man), GeneCard, STRING, and others online databases are used for building a series of network, and selecting the core target and analyzing the signal pathway. Finally, we make molecular docking predictions for the important compounds. The results showed that the Qingfei Paidu decoction compound-pneumonia target network contained 292 compounds and 214 corresponding targets, and the core targets involved AKT1 (AKT serine/threonine kinase 1), IL6 (interleukin 6), MAPK8 (mitogen-activated protein kinase 8), MAPK1 (mitogen-activated protein kinase 1), and JUN (jun proto-oncogene). GO (Gene Ontology) function enrichment analysis yielded 858 GO entries, and KEGG (Kyoto Encyclopedia of Genes and Genomes) enrichment screening yielded 122 related pathways, including hypoxia inducible factor-1 (HIF-1) and Toll-like receptor (TLRs) signaling pathways related to pneumonia, as well as T-cell receptor (TCR) signaling pathway related to lung injury protection. The molecular docking results showed that some core compounds of the Chinese herbal medicine of Qingfei Paidu decoction have a certain degree of affinity for 2019-novel coronavirus (2019-nCoV) main protease (3C-like protease, 3CLpro) and angiotensin-converting enzyme 2 (ACE2). In this paper, we preliminarily explored the potential therapeutic mechanism for Qingfei Paidu decoction to against COVID-19 and predicted the active ingredients. We hope that the results will help to the further study on the active ingredients and mechanism of Qingfei Paidu decoction to COVID-19.
7. Expert consensus on emergency surgery management for traumatic orthopedics under prevention and control of novel coronavirus pneumonia
Jing LIU ; Hui LI ; Wu ZHOU ; Guohui LIU ; Yingze ZHANG ; Baoguo JIANG ; Peifu TANG ; Guodong LIU ; Xinbao WU ; Zhi YUAN ; Fang ZHOU ; Tianbing WANG ; Zhongguo FU ; Zhiyong HOU ; Jiacan SU ; Bin YU ; Zengwu SHAO ; Tian XIA ; Liming XIONG ; Yue FANG ; Guanglin WANG ; Peng LIN ; Yanxi CHEN ; Jiangdong NI ; Lei YANG ; Dongliang WANG ; Chengjian HE ; Ximing LIU ; Biao CHE ; Yaming LI ; Junwen WANG ; Ming CHEN ; Meng ZHAO ; Faqi CAO ; Yun SUN ; Bobin MI ; Mengfei LIU ; Yuan XIONG ; Hang XUE ; Liangcong HU ; Yiqiang HU ; Lang CHEN ; Chenchen YAN
Chinese Journal of Trauma 2020;36(2):111-116
Since December 2019, novel coronavirus pneumonia (NCP) has been reported in Wuhan, Hubei Province, and spreads rapidly to all through Hubei Province and even to the whole country. The virus is 2019 novel coronavirus (2019-nCoV), never been seen previously in human, but all the population is generally susceptible. The virus spreads through many ways and is highly infectious, which brings great difficulties to the prevention and control of NCP. Based on the needs of orthopedic trauma patients for emergency surgery and review of the latest NCP diagnosis and treatment strategy and the latest principles and principles of evidence-based medicine in traumatic orthopedics, the authors put forward this expert consensus to systematically standardize the clinical pathway and protective measures of emergency surgery for orthopedic trauma patients during prevention and control of NCP and provide reference for the emergency surgical treatment of orthopedic trauma patients in hospitals at all levels.
8.Expression Levels of JARID1B, Hes1 and MMP-9 Genes in CML Patients Treated with Imatinib Mesylate.
Zhi-Kai HE ; Seng XUE ; Yong-Hong ZHANG ; Lin LI ; Yun-Jin XIA ; Xiang WANG ; Xin SHI ; Yu LIU ; Zheng XU ; Chen LI ; Jing-Xuan ZHANG
Journal of Experimental Hematology 2019;27(4):1071-1076
OBJECTIVE:
To explore the relationship between the expression levels of JARID1B,Hes1 and MMP-9 genes and the stages of chronic myelogenous leukemia(CML) and the curative effect of imatinib mesylate (IM).
METHODS:
Peripheral blood samples of 15 cases of CML in chronic phase and 10 cases of CML in progressive phase were collected from the Hematology Department of Taihe Hospital affiliated to Hubei University of Medicine and 15 cases of healthy people in the Physical Examination Center. CML patients were divided into effective group and ineffective group based on the efficacy after treatment with IM, then real-time PCR was used to detect the expression levels of JARID1B, Hes1 and MMP-9 mRNA, finally, the differences in the level of gene expression and their correlations with CML stages and IM curative efficacy were analysed.
RESULTS:
The expression levels of Hes1 and MMP-9 in initially diagnosed patients in chronic and progressive phase without IM treatment were significantly higher than those of health people(P<0.05). There was no significant difference in the expression level of JARID1B between chronic phase patients and health people(P>0.05), but the expression level of JARID1B in the progressive phase patients was higher than that of health people (P<0.05). The expression levels of JARID1B and Hes1 in the IM-effective group were not significantly different from those in the IM-ineffective group (P=0.85,P=0.82), while the expression level of MMP-9 in the IM-effective group [JP2]was significantly lower than that in the IM-ineffective group(P<0.05).
CONCLUSION
The expression levels of JARID1B Hes1 and MMP-9 relate with the different phase of CML; The expression levels of JARID1B and Hes1 have not significant relationship with IM curative efficacy, the MMP-9 gene expression level relates with IM curative efficacy.
Antineoplastic Agents
;
therapeutic use
;
Humans
;
Imatinib Mesylate
;
therapeutic use
;
Jumonji Domain-Containing Histone Demethylases
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
drug therapy
;
Matrix Metalloproteinase 9
;
Nuclear Proteins
;
Repressor Proteins
;
Transcription Factor HES-1
9.Effects and Predictive Factors of Immunosuppressive Therapy Combined with Umbilical Cord Blood Infusion in Patients with Severe Aplastic Anemia.
Xia ZHANG ; Zhangzhi LI ; Wei GENG ; Bin SONG ; Chucheng WAN
Yonsei Medical Journal 2018;59(5):643-651
PURPOSE: To investigate the efficacy and safety of umbilical cord blood (UCB) infusion (UCBI) plus immunosuppressive therapy (IST) treatment in comparison to IST treatment, as well as predictive factors for clinical responses, in severe aplastic anemia (SAA) patients. MATERIALS AND METHODS: Totally, 93 patients with SAA were enrolled in this cohort study. In the IST group, rabbit antithymocyte globulin (r-ATG) combined with cyclosporine A (CsA) was administered, while in the IST+UBCI group, r-ATG, CsA, and UCB were used. RESULTS: After 6 months of treatment, UCBI+IST achieved a higher complete response (CR) rate (p=0.002) and an elevated overall response rate (ORR) (p=0.004), compared to IST. Regarding hematopoietic recovery at month 6, platelet responses in the UCBI+IST group were better than those in the IST group (p=0.002), and UCBI+IST treatment facilitated increasing trends in absolute neutrophil count (ANC) response (p=0.056). Kaplan-Meier curves illuminated UCBI+IST achieved faster ANC response (p < 0.001) and platelet response (p < 0.001), compared with IST therapy. There was no difference in overall survival (OS) between the two groups (p=0.620). Furthermore, logistic regression analysis demonstrated that UCBI+IST was an independent predicting factor for both CR (p=0.001) and ORR (p < 0.001), compared to IST; meanwhile, very severe aplastic anemia (VSAA) and ANC could predict clinical responses as well. However, Cox proportional hazard regression indicated that VSAA (p=0.003), but not UCBI+IST, affected OS. Safety profiles showed that UCBI+IST therapy did not elevate adverse events, compared with IST treatment. CONCLUSION: UCBI+IST achieved better clinical responses and hematopoietic recovery than IST, and was well tolerated in SAA patients.
Anemia, Aplastic*
;
Antilymphocyte Serum
;
Blood Platelets
;
Cohort Studies
;
Cyclosporine
;
Fetal Blood*
;
Humans
;
Logistic Models
;
Neutrophils
;
Umbilical Cord*
10.Clinical features of mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes syndrome in twin brothers
Li YANG ; Yufen LI ; Liyun XU ; Shiyan QIU ; Shaoxia SUN ; Piqiang ZHANG ; Bing XIA
Journal of Clinical Pediatrics 2017;35(1):42-45
Objective To explore the clinical features of mitochondrial encephalomyopathy lactic acidosis and strokelike episodes (MELAS) syndrome in fratemal twins brothers.Methods The clinical data,the results of laboratory examinations,electroencephalogram (EEG),imaging,and gene detection,and the process of diagnosis and treatment were retrospectively analyzed the fraternal twin brothers with MELAS syndrome.Results The proband,a 7-year-old male,had intermittent headaches,vomit and twitching at onset.He suffered from exercise intolerance,fatigue,accompanied by short stature and hairy.The fasting blood lactic acid level was increased.Multiple video EEG showed the slowdown of background activity.Head MRI showed recurrent lesions with the characteristics of migration and variation.The point mutation rate of mtDNA A3243G was 34.7%.The diagnosis of MELAS was confirmed.At the same time,his fraternal twin brother was screened and found that his point mutation rate of A3243G was 30.0%.Although there was no clinical symptom at that time,he was onset with convulsion after 3 years.Conclusions Gene detection and family screening are helpful for the early diagnosis of MELAS.The mutation rate of A3243G is very high,which can cause an early onset and serious clinical symptoms.


Result Analysis
Print
Save
E-mail